News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
581,184 Results
Type
Article (19095)
Company Profile (166)
Press Release (561992)
Multimedia
Podcasts (78)
Webinars (13)
Section
Business (198427)
Career Advice (707)
Deals (30752)
Drug Delivery (89)
Drug Development (65652)
Employer Resources (54)
FDA (12412)
Job Trends (11104)
News (287909)
Policy (24150)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (822)
Accelerated approval (43)
ADA (26)
Adcomms (10)
Allergies (143)
Alliances (41818)
ALS (143)
Alzheimer's disease (1271)
Antibody-drug conjugate (ADC) (350)
Approvals (13038)
Artificial intelligence (509)
ASCO (219)
Autoimmune disease (251)
Automation (40)
Bankruptcy (319)
Best Places to Work (8374)
BIO (47)
BIOSECURE Act (10)
Biosimilars (190)
BioSpace Insights (77)
Biotechnology (102)
Bladder cancer (155)
Brain cancer (55)
Breast cancer (603)
Cancer (4472)
Cardiovascular disease (353)
Career advice (611)
Career pathing (15)
CAR-T (218)
CDC (8)
Celiac Disease (1)
Cell therapy (611)
Cervical cancer (41)
Clinical research (58861)
Collaboration (1727)
Commercialization (4)
Company closure (2)
Compensation (1476)
Complete response letters (61)
COVID-19 (1285)
CRISPR (82)
C-suite (1049)
Cystic fibrosis (126)
Data (6621)
Decentralized trials (1)
Denatured (23)
Depression (125)
Dermatology (67)
Diabetes (441)
Diagnostics (4826)
Digital health (44)
Diversity (3)
Diversity, equity & inclusion (16)
Drug discovery (269)
Drug pricing (126)
Drug shortages (15)
Duchenne muscular dystrophy (230)
Earnings (81367)
Editorial (25)
Employer branding (5)
Employer resources (50)
Events (99245)
Executive appointments (962)
FDA (15563)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (20)
Frontotemporal dementia (27)
Funding (1226)
Gene editing (164)
Generative AI (35)
Gene therapy (459)
GLP-1 (674)
Government (2016)
Grass and pollen (5)
Guidances (332)
Healthcare (11047)
Hematology (128)
HIV (55)
Huntington's disease (28)
IgA nephropathy (99)
Immunology and inflammation (168)
Immuno-oncology (76)
Indications (195)
Infectious disease (1517)
Inflammatory bowel disease (173)
Inflation Reduction Act (9)
Influenza (97)
Intellectual property (296)
Interviews (94)
IPO (13979)
IRA (33)
Job creations (3104)
Job search strategy (553)
JPM (29)
Kidney cancer (20)
Labor market (39)
Layoffs (253)
Leadership (11)
Legal (6589)
Licensing (8)
Liver cancer (55)
Longevity (22)
Lung cancer (633)
Lymphoma (343)
Machine learning (35)
Management (18)
Manufacturing (909)
Marketing (12)
MASH (164)
Medical affairs (1)
Medical device (9260)
Medtech (9409)
Mergers & acquisitions (17943)
Metabolic disorders (1065)
mRNA (108)
Multiple sclerosis (139)
NASH (15)
Neurodegenerative disease (299)
Neuropsychiatric disorders (70)
Neuroscience (2431)
Neurotech (1)
NextGen: Class of 2026 (3900)
Non-profit (1268)
Now hiring (24)
Obesity (427)
Opinion (158)
Ovarian cancer (175)
Pain (242)
Pancreatic cancer (226)
Parkinson's disease (278)
Partnered (21)
Patents (581)
Patient recruitment (594)
Peanut (39)
People (50693)
Pharmaceutical (45)
Pharmacy benefit managers (23)
Phase 1 (18150)
Phase 2 (25887)
Phase 3 (19199)
Pipeline (8665)
Policy (165)
Postmarket research (2127)
Preclinical (7534)
Press Release (49)
Prostate cancer (236)
Psychedelics (31)
Radiopharmaceuticals (269)
Rare diseases (853)
Real estate (4461)
Recruiting (20)
Regulatory (19736)
Reports (27)
Research institute (960)
Resumes & cover letters (96)
Rett syndrome (42)
RNA editing (12)
RSV (53)
Schizophrenia (145)
Series A (222)
Series B (157)
Service/supplier (5)
Sickle cell disease (97)
Special edition (11)
Spinal muscular atrophy (113)
Sponsored (15)
Startups (2785)
State (2)
Stomach cancer (8)
Supply chain (95)
Tariffs (71)
The Weekly (53)
Vaccines (510)
Venture capital (56)
Weight loss (227)
Women's health (101)
Worklife (4)
Date
Last 7 days (535)
Last 30 days (1870)
Last 365 days (23075)
2026 (14727)
2025 (23302)
2024 (27247)
2023 (31379)
2022 (40752)
2021 (43344)
2020 (39854)
2019 (29697)
2018 (22653)
2017 (24686)
2016 (23533)
2015 (29435)
2014 (25675)
2013 (22074)
2012 (24093)
2011 (24443)
2010 (23671)
Location
Africa (467)
Alabama (81)
Alaska (2)
Arizona (330)
Arkansas (13)
Asia (30157)
Australia (4147)
California (12605)
Canada (3441)
China (1033)
Colorado (508)
Connecticut (463)
Delaware (272)
Europe (54662)
Florida (1924)
Georgia (404)
Hawaii (3)
Idaho (49)
Illinois (852)
India (95)
Indiana (553)
Iowa (15)
Japan (557)
Kansas (119)
Kentucky (36)
Louisiana (30)
Maine (28)
Maryland (1359)
Massachusetts (8660)
Michigan (324)
Minnesota (601)
Mississippi (5)
Missouri (104)
Montana (27)
Nebraska (16)
Nevada (116)
New Hampshire (68)
New Jersey (3175)
New Mexico (18)
New York (3098)
North Carolina (1509)
North Dakota (4)
Northern California (6315)
Ohio (301)
Oklahoma (16)
Oregon (31)
Pennsylvania (2397)
Puerto Rico (26)
Rhode Island (36)
South America (733)
South Carolina (79)
South Dakota (1)
Southern California (5191)
Tennessee (147)
Texas (2021)
United States (42685)
Utah (384)
Vermont (1)
Virginia (264)
Washington D.C. (51)
Washington State (980)
West Virginia (2)
Wisconsin (103)
Wyoming (1)
581,184 Results for "jazz pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline
Jazz Pharmaceuticals is reaching into its wallet once again, this time buying Actio Biosciences and an experimental therapy for KCNT1+ epilepsy, a form of the disease with no FDA-approved treatments.
August 10, 2026
·
2 min read
·
Gabrielle Masson
Deals
Jazz strikes new chord with AbCellera in T cell engager pact that could top $2.4B
Jazz Pharmaceuticals is diversifying its oncology strategy, orchestrating a new antibody deal with AbCellera that offers $56 million upfront, plus $792 million in biobucks for each of the three initial programs.
June 17, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
June 17, 2026
·
3 min read
Stomach cancer
Jazz’s Ziihera Shows ‘Practice-Changing’ Efficacy in Stomach Cancer
Jazz’s Ziihera and BeOne’s Tevimbra plus chemotherapy led to what Truist Securities dubbed one of the strongest overall survival signals ever reported in a type of gastroesophageal cancer.
January 7, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference
April 7, 2026
·
1 min read
Press Releases
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions
January 8, 2026
·
3 min read
Business
Jazz Sells Priority Review Voucher for $200M as Program’s Renewal Languishes in Senate
Half of the net proceeds will go to Jazz; it remains unclear who will get the remaining sum. Jazz did not reveal the buyer of the voucher.
January 15, 2026
·
2 min read
·
Tristan Manalac
Stomach cancer
Jazz, Zymeworks Bispecific Achieves ‘Practice-Changing’ Results in Stomach Cancer Study
With positive data from the Phase III HERIZON-GEA-01 study, Zymeworks and Jazz Pharmaceuticals will file an approval application for Ziihera in the first half of 2026 for the treatment of gastroesophageal adenocarcinoma.
November 18, 2025
·
2 min read
·
Tristan Manalac
Brain cancer
FDA Greenlights Jazz’s Dordaviprone, First New Treatment for Ultra-Rare Brain Tumor
The small molecule drug, acquired by Jazz Pharmaceuticals in its $935 million Chimerix pick-up this spring, is intended for relapsed adult and pediatric patients with H3 K27M mutations.
August 6, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
Late-breaking HERIZON-GEA-01 presentation highlights the expanding clinical profile of Ziihera across HER2-driven gastrointestinal cancers Jazz to host investor webcast on Friday, January 9, 2026, to review data
December 2, 2025
·
15 min read
1 of 58,119
Next
